Serum syndecan-1: A new independent prognostic marker in multiple myeloma

Blood

Volumn 95, Issue 2, 2000, Pages 388-392

  Seidel, Carina ^a   Sundan, Anders ^b   Hjorth, Martin ^b   Turesson, Ingemar ^b   Dahl, Inger Marie S ^b   Abildgaard, Niels ^b   Waage, Anders ^b   Børset, Magne ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; COLLAGEN TYPE 1; CREATININE; INTERLEUKIN 6; SYNDECAN; SYNDECAN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE;

EID: 0034650981     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.388     Document Type: Article

References (30)

1. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J. 1997;327:1-16.
2. Koda JE, Rapraeger A, Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells: cell surface proteoglycan as a receptor for interstitial collagens. J Biol Chem. 1985;260: 8157-8162.
3. Sanderson RD, Sneed TB, Young LA, Sullivan GL, Lander AD. Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by integral membrane proteoglycan, syndecan. J Immunol. 1992;148:3902-3911.
4. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. 1993;81:767-774.
5. Saunders S, Bernfield M. Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix. J Cell Biol. 1988;106:423-430.
6. Sun X, Mosher DF, Rapraeger A. Heparan sulfate-mediated binding of epithelial cell surface proteoglycan to thrombospondin. J Biol Chem. 1989;264:2885-2889.
7. Filla MS, Dam P, Rapraeger AC. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J Cell Physiol. 1998;174:310-321.
8. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1989;1:27-35.
9. Wijdenes J, Vooijs WC, Clement C, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996;94: 318-323.
10. Witzig TE, Kimlinger T, Stenson M, Therneau T. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and b-cell chronic lymphocytic leukemia. Leukemia and Lymphoma. 1998; 51:167-175.
11. Jourdan M, Ferlin M, Legouffe E, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998;100:637-646.
12. Borset M, Helseth E, Naume B, Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol. 1993;85:446-451.
13. Dhodapkar MV, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood. 1998; 91:2679-2688.
14. Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RO. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol. 1997;99:368-371.
15. The Nordic Myeloma Study Group. Interferonalpha 2b added to melphalan-prednisone tor initial and maintenance therapy in multiple myeloma: a randomized, controlled trial. Ann Intern Med. 1996;124:212-222.
16. Durie BG, Salmon DE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer. 1975;36:842-854.
17. Seidel C, Børset M, Turesson I, Abildgaard N, Sundan A, Waage A, for The Nordic Myeloma Study Group. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood. 1998;91:806-812.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53.
19. Cox DR. Regression models and life tables. JR Stat Soc. 1982;34.
20. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733-737.
21. Davies FE, Jack AS, Morgan GJ. The use of biological variables to predict outcome in multiple myeloma. Br J Haematol. 1997;99:719-725.
22. Joshua DE, Brown RD, Gibson J. Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease. Leuk Lymphoma. 1994;15:375-381.
23. Durie BG, Stock-Novack D, Salmon SE, et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood. 1990;75:823-830.
24. Boccadoro M, Gallone G, Friert R, Pileri A, Bataille R, Klein B. Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? Blood. 1993;82:3507-3508.
25. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101:189-194.
26. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382-3387.
27. Witzig TE, Gertz MA, Lust JA, Kyle RA, O'Fallon WM, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood. 1996;88:1780-1787.
28. Salmon SE, Smith BA. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest. 1970;1114-1118.
29. Ohtani K, Ninomiya H, Hasegawa Y, et al. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Br J Haematol. 1995;91:116-120.
30. Turessan I, Abildgaard N, Ahlgren T, et al. Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. Br J Haematol. 1999;106:1005-1112.